TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Decreased by Hood River Capital Management LLC

Hood River Capital Management LLC reduced its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,455,323 shares of the biopharmaceutical company's stock after selling 175,026 shares during the period. Hood River Capital Management LLC owned about 0.93% of TG Therapeutics worth $43,805,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its position in shares of TG Therapeutics by 264.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 297,101 shares of the biopharmaceutical company's stock worth $8,944,000 after acquiring an additional 215,601 shares during the last quarter. State of Tennessee Department of Treasury grew its stake in TG Therapeutics by 28.4% during the 4th quarter. State of Tennessee Department of Treasury now owns 59,883 shares of the biopharmaceutical company's stock valued at $1,802,000 after purchasing an additional 13,228 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in TG Therapeutics by 937.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 32,498 shares of the biopharmaceutical company's stock worth $978,000 after purchasing an additional 29,366 shares during the last quarter. MYDA Advisors LLC raised its position in shares of TG Therapeutics by 37.5% in the 4th quarter. MYDA Advisors LLC now owns 55,000 shares of the biopharmaceutical company's stock valued at $1,656,000 after purchasing an additional 15,000 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in shares of TG Therapeutics by 4.7% during the 4th quarter. MetLife Investment Management LLC now owns 84,360 shares of the biopharmaceutical company's stock valued at $2,539,000 after buying an additional 3,752 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

TGTX stock traded down $0.15 during midday trading on Monday, reaching $41.18. The company had a trading volume of 892,825 shares, compared to its average volume of 3,077,535. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a 50 day moving average price of $37.18 and a 200 day moving average price of $32.59. The firm has a market capitalization of $6.54 billion, a PE ratio of -412.01 and a beta of 2.14. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on TGTX shares. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.